Medicus Pharma's Recent Debt Deal Extends Cash Runway to 24 Months
MDCX sits 38% above its 52-week low of $0.25.
Summary
Medicus Pharma is now estimated to have approximately 24 months of operating cash runway. This follows the company's recent securing of $22.8 million in high-cost secured debt, which provided a net cash infusion of $17 million, as disclosed yesterday. Given the company's severe financial distress, including a going concern warning and Nasdaq delisting notice, this extended runway significantly alleviates immediate liquidity concerns. It provides critical time for the company to execute its strategy, including a planned reverse stock split and advancing its drug pipeline.
At the time of this announcement, MDCX was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.5M. The 52-week trading range was $0.25 to $7.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.